Loi S, Adams S, Schmid P, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. ESMO 2017 Congress; abstract LBA13.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker